• Positive review of hospitalized COVID-19 patients triggers approval to move from Part 1 to Part 2 of the trial
• Top dose of 1800 mg Veyonda daily to be used in final patient cohort
• Tests on blood cytokine levels in Part 1 patients underway
For more information, please download the attached PDF
Download this document
